Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis‐targeted, disease‐modifying strategy
Identifieur interne : 004F11 ( Main/Merge ); précédent : 004F10; suivant : 004F12Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis‐targeted, disease‐modifying strategy
Auteurs : C. Warren Olanow [États-Unis] ; Joseph Jankovic [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-05.
English descriptors
- KwdEn :
- Anti-Inflammatory Agents, Non-Steroidal (therapeutic use), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Coenzymes, Cyclooxygenase 1, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors, Cyclooxygenase Inhibitors (therapeutic use), Dose-Response Relationship, Drug, Dyskinesia, Drug-Induced (etiology), Dyskinesia, Drug-Induced (prevention & control), Humans, Indans (therapeutic use), Levodopa (adverse effects), Levodopa (therapeutic use), Membrane Proteins, N-Methylaspartate (antagonists & inhibitors), Neuroprotective Agents (therapeutic use), Parkinson Disease (drug therapy), Parkinson's disease, Prostaglandin-Endoperoxide Synthases (metabolism), Ubiquinone (analogs & derivatives), Ubiquinone (therapeutic use), Vitamin E (therapeutic use), levodopa, motor complications.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , analogs & derivatives : Ubiquinone.
- chemical , antagonists & inhibitors : N-Methylaspartate.
- chemical , metabolism : Prostaglandin-Endoperoxide Synthases.
- chemical , therapeutic use : Anti-Inflammatory Agents, Non-Steroidal, Antiparkinson Agents, Cyclooxygenase Inhibitors, Indans, Levodopa, Neuroprotective Agents, Ubiquinone, Vitamin E.
- chemical : Coenzymes, Cyclooxygenase 1, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors, Membrane Proteins.
- drug therapy : Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- prevention & control : Dyskinesia, Drug-Induced.
- Dose-Response Relationship, Drug, Humans.
Abstract
The introduction of levodopa in the late 1960s represented a landmark in the therapy of Parkinson's disease (PD). However, motor complications of chronic levodopa therapy have emerged as a major limitation of this otherwise effective therapy. Advancing medical and surgical treatment of these complications has been the main objective of clinical trials during the past few decades. In addition, basic research has focused on better understanding of the mechanisms of motor complications and how to prevent them. Slowing or delaying the progression of the disease delays the need for levodopa therapy; therefore, neuroprotective strategies may play an important role in preventing the onset and reducing the severity of levodopa‐related adverse effects. In this introductory review, we present the rationale for current and experimental therapies designed to favorably modify the progression of PD. If implemented early in the course of the disease, such treatments, if found effective, may not only alter the natural progression of the disease but may also delay or minimize motor and nonmotor complications associated with levodopa. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20457
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000986
- to stream Istex, to step Curation: 000986
- to stream Istex, to step Checkpoint: 002234
- to stream PubMed, to step Corpus: 003077
- to stream PubMed, to step Curation: 003077
- to stream PubMed, to step Checkpoint: 003042
- to stream Ncbi, to step Merge: 001224
- to stream Ncbi, to step Curation: 001224
- to stream Ncbi, to step Checkpoint: 001224
Links to Exploration step
ISTEX:DF73A43304D380D59CAAA08D53BAD53717B6DB49Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis‐targeted, disease‐modifying strategy</title><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DF73A43304D380D59CAAA08D53BAD53717B6DB49</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20457</idno><idno type="url">https://api.istex.fr/document/DF73A43304D380D59CAAA08D53BAD53717B6DB49/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000986</idno><idno type="wicri:Area/Istex/Curation">000986</idno><idno type="wicri:Area/Istex/Checkpoint">002234</idno><idno type="wicri:doubleKey">0885-3185:2005:Olanow C:neuroprotective:therapy:in</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15822111</idno><idno type="wicri:Area/PubMed/Corpus">003077</idno><idno type="wicri:Area/PubMed/Curation">003077</idno><idno type="wicri:Area/PubMed/Checkpoint">003042</idno><idno type="wicri:Area/Ncbi/Merge">001224</idno><idno type="wicri:Area/Ncbi/Curation">001224</idno><idno type="wicri:Area/Ncbi/Checkpoint">001224</idno><idno type="wicri:doubleKey">0885-3185:2005:Olanow C:neuroprotective:therapy:in</idno><idno type="wicri:Area/Main/Merge">004F11</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis‐targeted, disease‐modifying strategy</title><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-05">2005-05</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">S11</biblScope><biblScope unit="supplement">11</biblScope><biblScope unit="page" from="S3">S3</biblScope><biblScope unit="page" to="S10">S10</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">DF73A43304D380D59CAAA08D53BAD53717B6DB49</idno><idno type="DOI">10.1002/mds.20457</idno><idno type="ArticleID">MDS20457</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Coenzymes</term><term>Cyclooxygenase 1</term><term>Cyclooxygenase 2</term><term>Cyclooxygenase 2 Inhibitors</term><term>Cyclooxygenase Inhibitors (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Dyskinesia, Drug-Induced (prevention & control)</term><term>Humans</term><term>Indans (therapeutic use)</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Membrane Proteins</term><term>N-Methylaspartate (antagonists & inhibitors)</term><term>Neuroprotective Agents (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson's disease</term><term>Prostaglandin-Endoperoxide Synthases (metabolism)</term><term>Ubiquinone (analogs & derivatives)</term><term>Ubiquinone (therapeutic use)</term><term>Vitamin E (therapeutic use)</term><term>levodopa</term><term>motor complications</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Ubiquinone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>N-Methylaspartate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Prostaglandin-Endoperoxide Synthases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal</term><term>Antiparkinson Agents</term><term>Cyclooxygenase Inhibitors</term><term>Indans</term><term>Levodopa</term><term>Neuroprotective Agents</term><term>Ubiquinone</term><term>Vitamin E</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Coenzymes</term><term>Cyclooxygenase 1</term><term>Cyclooxygenase 2</term><term>Cyclooxygenase 2 Inhibitors</term><term>Membrane Proteins</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Dose-Response Relationship, Drug</term><term>Humans</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The introduction of levodopa in the late 1960s represented a landmark in the therapy of Parkinson's disease (PD). However, motor complications of chronic levodopa therapy have emerged as a major limitation of this otherwise effective therapy. Advancing medical and surgical treatment of these complications has been the main objective of clinical trials during the past few decades. In addition, basic research has focused on better understanding of the mechanisms of motor complications and how to prevent them. Slowing or delaying the progression of the disease delays the need for levodopa therapy; therefore, neuroprotective strategies may play an important role in preventing the onset and reducing the severity of levodopa‐related adverse effects. In this introductory review, we present the rationale for current and experimental therapies designed to favorably modify the progression of PD. If implemented early in the course of the disease, such treatments, if found effective, may not only alter the natural progression of the disease but may also delay or minimize motor and nonmotor complications associated with levodopa. © 2005 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.20457"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis‐targeted, disease‐modifying strategy</title><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DF73A43304D380D59CAAA08D53BAD53717B6DB49</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20457</idno><idno type="url">https://api.istex.fr/document/DF73A43304D380D59CAAA08D53BAD53717B6DB49/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000986</idno><idno type="wicri:Area/Istex/Curation">000986</idno><idno type="wicri:Area/Istex/Checkpoint">002234</idno><idno type="wicri:doubleKey">0885-3185:2005:Olanow C:neuroprotective:therapy:in</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis‐targeted, disease‐modifying strategy</title><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-05">2005-05</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">S11</biblScope><biblScope unit="supplement">11</biblScope><biblScope unit="page" from="S3">S3</biblScope><biblScope unit="page" to="S10">S10</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">DF73A43304D380D59CAAA08D53BAD53717B6DB49</idno><idno type="DOI">10.1002/mds.20457</idno><idno type="ArticleID">MDS20457</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>levodopa</term><term>motor complications</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The introduction of levodopa in the late 1960s represented a landmark in the therapy of Parkinson's disease (PD). However, motor complications of chronic levodopa therapy have emerged as a major limitation of this otherwise effective therapy. Advancing medical and surgical treatment of these complications has been the main objective of clinical trials during the past few decades. In addition, basic research has focused on better understanding of the mechanisms of motor complications and how to prevent them. Slowing or delaying the progression of the disease delays the need for levodopa therapy; therefore, neuroprotective strategies may play an important role in preventing the onset and reducing the severity of levodopa‐related adverse effects. In this introductory review, we present the rationale for current and experimental therapies designed to favorably modify the progression of PD. If implemented early in the course of the disease, such treatments, if found effective, may not only alter the natural progression of the disease but may also delay or minimize motor and nonmotor complications associated with levodopa. © 2005 Movement Disorder Society</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.</title><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Mount Sinai School of Medicine, Annenberg 14-94, One Gustave L. Levy Place, New York, NY 10029, USA. warren.olanow@mssm.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, Annenberg 14-94, One Gustave L. Levy Place, New York, NY 10029</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="doi">10.1002/mds.20457</idno><idno type="RBID">pubmed:15822111</idno><idno type="pmid">15822111</idno><idno type="wicri:Area/PubMed/Corpus">003077</idno><idno type="wicri:Area/PubMed/Curation">003077</idno><idno type="wicri:Area/PubMed/Checkpoint">003042</idno><idno type="wicri:Area/Ncbi/Merge">001224</idno><idno type="wicri:Area/Ncbi/Curation">001224</idno><idno type="wicri:Area/Ncbi/Checkpoint">001224</idno><idno type="wicri:doubleKey">0885-3185:2005:Olanow C:neuroprotective:therapy:in</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.</title><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Mount Sinai School of Medicine, Annenberg 14-94, One Gustave L. Levy Place, New York, NY 10029, USA. warren.olanow@mssm.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, Annenberg 14-94, One Gustave L. Levy Place, New York, NY 10029</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Coenzymes</term><term>Cyclooxygenase 1</term><term>Cyclooxygenase 2</term><term>Cyclooxygenase 2 Inhibitors</term><term>Cyclooxygenase Inhibitors (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Dyskinesia, Drug-Induced (prevention & control)</term><term>Humans</term><term>Indans (therapeutic use)</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Membrane Proteins</term><term>N-Methylaspartate (antagonists & inhibitors)</term><term>Neuroprotective Agents (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Prostaglandin-Endoperoxide Synthases (metabolism)</term><term>Ubiquinone (analogs & derivatives)</term><term>Ubiquinone (therapeutic use)</term><term>Vitamin E (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Ubiquinone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>N-Methylaspartate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Prostaglandin-Endoperoxide Synthases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal</term><term>Antiparkinson Agents</term><term>Cyclooxygenase Inhibitors</term><term>Indans</term><term>Levodopa</term><term>Neuroprotective Agents</term><term>Ubiquinone</term><term>Vitamin E</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Coenzymes</term><term>Cyclooxygenase 1</term><term>Cyclooxygenase 2</term><term>Cyclooxygenase 2 Inhibitors</term><term>Membrane Proteins</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Dose-Response Relationship, Drug</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The introduction of levodopa in the late 1960s represented a landmark in the therapy of Parkinson's disease (PD). However, motor complications of chronic levodopa therapy have emerged as a major limitation of this otherwise effective therapy. Advancing medical and surgical treatment of these complications has been the main objective of clinical trials during the past few decades. In addition, basic research has focused on better understanding of the mechanisms of motor complications and how to prevent them. Slowing or delaying the progression of the disease delays the need for levodopa therapy; therefore, neuroprotective strategies may play an important role in preventing the onset and reducing the severity of levodopa-related adverse effects. In this introductory review, we present the rationale for current and experimental therapies designed to favorably modify the progression of PD. If implemented early in the course of the disease, such treatments, if found effective, may not only alter the natural progression of the disease but may also delay or minimize motor and nonmotor complications associated with levodopa.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004F11 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004F11 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:DF73A43304D380D59CAAA08D53BAD53717B6DB49
|texte= Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis‐targeted, disease‐modifying strategy
}}
| This area was generated with Dilib version V0.6.23. |  |